The alopecia areata market is expected to grow significantly as awareness of the condition increases, potentially expanding further in the coming years, supported by rising prevalence. Additionally, the launch of emerging therapies such as RINVOQ (AbbVie), Bempikibart (Q32 Bio), Coacillium (Legacy Healthcare), ALM 223 (Almirall), Amlitelimab (Sanofi), HCW9302 (HCW Biologics), ALY-101 (ALYS Pharmaceuticals), DR-01 (Dren Bio), Rezpegaldesleukin (Nektar Therapeutics), and others will further propel the market growth.

LAS VEGAS, Feb. 19, 2026 /PRNewswire/ -- Recently published Alopecia Areata Market Insights report includes a comprehensive understanding of current treatment practices, alopecia areata emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. 

Alopecia Areata Market Summary

• The total alopecia areata treatment market size is expected to grow positively by 2036 in the leading markets.
• The United States accounts for the largest market size of alopecia areata, in comparison to EU4 (Germany, Italy, France, and Spain), the UK, and Japan.
• In 2025, the total diagnosed prevalent cases of alopecia areata in the 7MM were found to be 1.7 million. 
• Leading alopecia areata companies, such as AbbVie (NYSE: ABBV), Q32 Bio (NASDAQ: QTTB), Legacy Healthcare, Almirall (BME: ALM), Sanofi (EPA: SAN), HCW Biologics (NASDAQ: HCWB), ALYS Pharmaceuticals, Dren Bio, Nektar Therapeutics (NASDAQ: NKTR), and others, are developing new alopecia areata treatment drugs that can be available in the alopecia areata market in the coming years. 
• The promising alopecia areata therapies in clinical trials include RINVOQ, Bempikibart, Coacillium, ALM 223, Amlitelimab, HCW9302, ALY-101, DR-01, Rezpegaldesleukin, and others.

Discover what will the alopecia areata market be worth in 2036 @ https://www.delveinsight.com/sample-request/alopecia-areata-market?utm_source=cision&utm_medium=pressrelease&utm_campaign=spr

Key Factors Driving the Growth of the Alopecia Areata Market 

• Growing Alopecia Areata Target Patient Pool: In 2024, the United States recorded the highest number of diagnosed prevalent cases of alopecia areata among the 7MM. DelveInsight estimated approximately 620K diagnosed cases in the US that year, with projections indicating a continued increase throughout the forecast period.
• Approval of JAK Inhibitors: The first systemic, targeted medicines for alopecia areata, notably baricitinib (OLUMIANT) and ritlecitinib (LITFULO), changed the treatment landscape by providing reproducible, clinically meaningful hair regrowth in controlled trials. Regulatory clearances create prescribing options, attract payer attention, and validate JAK inhibition as a therapeutic approach.
• Emergence of OX40L and IL-2 Inhibitors: Emerging therapies, including OX40L and IL-2 inhibitors, are strengthening the alopecia areata landscape by targeting the disease's root causes and offering precision in treatment.
• Expected Launch of Alopecia Areata Therapies: The dynamics of the alopecia areata market are expected to change in the coming years due to the launch of emerging therapies such as RINVOQ (AbbVie), Bempikibart (Q32 Bio), Coacillium (Legacy Healthcare), ALM 223 (Almirall), Amlitelimab (Sanofi), HCW9302 (HCW Biologics), ALY-101 (ALYS Pharmaceuticals), DR-01 (Dren Bio), Rezpegaldesleukin (Nektar Therapeutics), and others.

Aparna Thakur, Assistant Project Manager, Forecasting and Analytics at DelveInsight, commented that a limited number of therapies are currently approved for the treatment of alopecia areata, underscoring the field's strong emphasis on immune-modulating mechanisms. Approved options include OLUMIANT, a small-molecule JAK inhibitor co-developed by Eli Lilly and Company and Incyte Corporation; LITFULO, a selective JAK3 and TEC kinase inhibitor from Pfizer; and LEQSELVI, a JAK1/JAK2 inhibitor developed by Sun Pharmaceutical Industries.

Despite these advancements, a substantial unmet need persists, as currently available treatments do not consistently deliver durable or complete disease control across patient populations. This therapeutic gap continues to drive innovation, positioning next-generation, differentiated therapies as key opportunities to improve clinical outcomes and expand the treatment landscape for alopecia areata.

Alopecia Areata Market Analysis

• The treatment landscape for alopecia areata has evolved into a comprehensive approach that combines pharmacological therapies with supportive care.
• The current market offers a broad range of treatment options, including corticosteroids, immunosuppressants, immunomodulators, and topical sensitizers or irritants.
• Corticosteroids continue to play a central role due to their anti-inflammatory effects, helping reduce immune-mediated attacks on hair follicles.
• Immunosuppressants and immunomodulators are typically used in more severe or treatment-resistant cases to regulate immune activity and prevent further hair loss.
• Topical sensitization therapies, including diphencyprone, work by inducing a mild allergic reaction that diverts the immune response away from hair follicles.
• Topical irritation therapies similarly create controlled irritation to stimulate immune modulation and promote hair regrowth.
• Minoxidil, a vasodilator, is frequently used off-label in alopecia areata to enhance blood flow to hair follicles and support regrowth.
• Dithranol is less commonly used but induces controlled inflammation to alter immune responses and encourage regrowth, mainly in patchy alopecia areata.
• Key market players such as Eli Lilly and Company, Incyte Corporation, Pfizer, and Sun Pharmaceuticals have introduced approved therapies, including OLUMIANT, LITFULO, and LEQSELVI across major markets.
• The growing demand for safer, more effective therapies is creating opportunities for innovative treatments that achieve durable remission without long-term use or serious safety risks.
• The entry of new therapies under development, such as RINVOQ (AbbVie), Bempikibart (Q32 Bio), Coacillium (Legacy Healthcare), ALM 223 (Almirall), Amlitelimab (Sanofi), HCW9302 (HCW Biologics), ALY-101 (ALYS Pharmaceuticals), DR-01 (Dren Bio), Rezpegaldesleukin (Nektar Therapeutics), and others, are expected to intensify competition and may reduce the market share of established treatments like LITFULO and OLUMIANT over time.

Alopecia Areata Competitive Landscape

Some of the alopecia areata drugs in the clinical trials include RINVOQ (AbbVie), Bempikibart (Q32 Bio), Coacillium (Legacy Healthcare), ALM 223 (Almirall), Amlitelimab (Sanofi), HCW9302 (HCW Biologics), ALY-101 (ALYS Pharmaceuticals), DR-01 (Dren Bio), Rezpegaldesleukin (Nektar Therapeutics), and others.

AbbVie's RINVOQ, an oral JAK1 inhibitor, has demonstrated potential efficacy in alopecia areata. While it is currently approved for indications such as rheumatoid arthritis and atopic dermatitis, emerging clinical evidence supports its possible use in alopecia areata. The therapy is presently undergoing Phase III clinical evaluation for this indication.

Legacy Healthcare's Coacillium, a botanical therapy developed by Legacy Healthcare, has shown encouraging results in the treatment of paediatric alopecia areata. Clinical studies reported notable hair regrowth, with sustained benefits observed even after treatment cessation.

Q32 Bio's Bempikibart is a fully human monoclonal antibody that targets both the Interleukin-7 Receptor Alpha (IL-7Rα) and Thymic Stromal Lymphopoietin (TSLP). It is designed to modulate adaptive immune responses in autoimmune disorders. The IL-7 and TSLP signaling pathways are biologically and genetically associated with T-cell-driven pathological mechanisms and play a key role in the development of multiple autoimmune diseases.

The anticipated launch of these emerging therapies are poised to transform the alopecia areata market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the alopecia areata market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.

Discover more about best emerging therapies for alopecia areata market @ Alopecia Areata Drugs Market 

Recent Developments in the Alopecia Areata Market

• In December 2025, Nektar Therapeutics reported topline data from the 36-week induction phase of its Phase 2b REZOLVE-AA study evaluating investigational rezpegaldesleukin, a first-in-class IL-2 pathway agonist designed to expand regulatory T cells (Tregs).
• In July 2025, AbbVie reported positive topline findings from the first of two pivotal Phase 3 trials in its UP-AA clinical program, assessing the safety and efficacy of upadacitinib (RINVOQ; 15 mg and 30 mg once daily) in adult and adolescent patients with severe alopecia areata, who had a mean baseline SALT score of 83.8, indicating approximately 16% scalp hair coverage.
• In July 2025, Nektar Therapeutics disclosed that the U.S. FDA had awarded Fast Track status to rezpegaldesleukin for the treatment of severe to very severe alopecia areata in adults and adolescents aged 12 years and above with a minimum body weight of 40 kg.

What is Alopecia Areata?

Alopecia areata is an autoimmune condition in which the body's immune system mistakenly attacks hair follicles, leading to hair loss. It typically presents as sudden, well-defined round or oval patches of hair loss on the scalp, but it can also affect the eyebrows, eyelashes, beard, or other body hair. The condition is non-scarring, meaning the hair follicles remain intact and hair can regrow, although the course is unpredictable and hair loss may recur. Alopecia areata can affect people of any age or gender and is often associated with other autoimmune conditions, but it is not contagious or life-threatening.

Alopecia Areata Epidemiology Segmentation

The alopecia areata epidemiology section provides insights into the historical and current alopecia areata patient pool and forecasted trends for the leading markets. DelveInsight's analysis suggests that prevalent cases of alopecia areata in the US accounted for nearly 35% of cases in the 7MM.

The alopecia areata treatment market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets, segmented into:

• Prevalent Cases of Alopecia Areata
• Diagnosed Prevalent Cases of Alopecia Areata
• Gender-specific Diagnosed Prevalent Cases of Alopecia Areata
• Age onset-based Diagnosed Prevalent Cases of Alopecia Areata
• Severity-specific Diagnosed Prevalent Cases of Alopecia Areata

Scope of the Alopecia Areata Market Report

• Therapeutic Assessment: Alopecia Areata current marketed and emerging therapies
• Alopecia Areata Market Dynamics: Key Market Forecast Assumptions of Emerging Alopecia Areata Drugs and Market Outlook
• Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Unmet Needs, KOL's views, Analyst's views, Alopecia Areata Market Access and Reimbursement

Download the report to understand what are the key drivers of alopecia areata market growth @ Alopecia Areata Market Forecast

Table of Contents

Related Reports

Alopecia Areata Clinical Trial Analysis

Alopecia Areata Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Alopecia Areata companies, including Concert Pharmaceuticals, Equillium, Maxinovel Pharmaceuticals, TechnoDerma Medicines, Sichuan Kelun-Biotech Biopharmaceutical, Pfizer, Reistone Biopharma Company Limited, and others.

JAK Inhibitors Market

JAK Inhibitors Market Size, Target Population, Competitive Landscape, and Market Forecast – 2034 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key JAK inhibitors companies, including Pfizer, AbbVie, Galapagos, Sierra Oncology, Theravance Biopharma, Dizal Pharmaceutical, Aclaris Therapeutics, Celon Pharma, Incyte Corporation, Gilead Sciences, Reistone Biopharma, Jiangsu Hengrui Medicine Co., MaxiNovel Pharmaceuticals, among others.

Interleukin-2 Inhibitors Market

Interleukin-2 Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast – 2034 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key IL-2 inhibitors companies, including Mural Oncology, Corvus Pharmaceuticals, Philogen, Merck, Nektar, Cue Biopharma, Krystal Biotech, ILTOO Pharma, Innovent, Regeneron Pharmaceuticals, R2T Biopharma (XEME Biopharma), AstraZeneca, GI Innovation, Merck, R2T Biopharma (XEME Biopharma), Sanofi, Synthekine, BioNTech, Medicenna Therapeutics, Ascendis Pharma, Sanofi, Synthorx, Cugene, AbbVie, Deka Biosciences, Dragonfly Therapeutics, Werewolf Therapeutics, Xilio Therapeutics, Bioniz Therapeutics, Equillium, Asher Bio, Synthekine, Anaveon, Aulos Bioscience, Selecxine, ProBio, Hoffmann-La Roche, TILT Biotherapeutics, among others.

Androgenetic Alopecia Market

Androgenetic Alopecia Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key androgenetic alopecia companies, including Kintor Pharmaceutical, Cosmo Pharmaceuticals, Merz Aesthetics, and others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us

Shruti Thakur
info@delveinsight.com
+14699457679
www.delveinsight.com 

Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/alopecia-areata-market-set-to-expand-by-2036-due-to-the-emergence-of-novel-drug-classes-such-as-ox40l-inhibitors-il-2-inhibitors-il-7r-and-others--delveinsight-302692254.html

SOURCE DelveInsight Business Research, LLP